Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 14;216(4):982–1000. doi: 10.1084/jem.20180870

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Gong et al.

This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 8. — sPD-L1 splicing variants mediate the resistance to PD-L1 blockade in MC38 syngeneic mouse model. (A) C57BL/6 mice bearing MC38/cont (n = 6), MC38/mPD-L1 (n = 6), MC38 (n = 10), MC38/mPD-L1v242 (n = 10), and MC38/mPD-L1v178 (n = 5) were intraperitoneally administrated 50 µg/mouse control IgG or 35 µg/mouse aPD-L1 antibody. The schedules for treatment are indicated by black arrows (control IgG) and red arrows (aPD-L1). Tumor volume is plotted individually. (B) Kaplan–Meier survival curves for mice bearing MC38 or MC38/mPD-L1v242. The survival curves were compared by applying the Gehan–Breslow–Wilcoxon test. ***, P < 0.001. (C and D) Representative IHC staining of mouse CD8, PD-1, and granzyme B was performed on day 21 for MC38/mPD-L1 (C) and MC38/mPD-L1v242 (D) xenograft tumors. Bars, 20 µm. Each experiment was independently performed twice, yielding similar results.